Interestingly, the resulting mesenchymal tumor cells had a CD44+CD24−/low phenotype with the ability to reestablish an epithelial tumor and increased drug resistance, which is consistent with breast CSCs [11]. This evidence concerns the gene CD44 and neoplasm.